Why I’m Writing This Samsung C&T Analysis — A Builder That Isn’t Only a Builder
After working through GS E&C, Daewoo E&C, DL E&C, and Samsung E&A in a row, it was a natural next step to look at Samsung C&T, Korea’s No.1-ranked builder by construction capability. But once I opened up its financials, it turned out hard to file this company under “builder” alone. Of its KRW 22.46 trillion in H1 2026 revenue, the construction division accounts for only about a third; the rest comes from trading, fashion, and resort businesses. On top of that, its debt ratio has steadily fallen from 84.52% in 2022 to 50.50% in 2025 — lower than any of the builders covered on this blog so far.
There are three questions I wanted to answer here. First, revenue drifted down gently from KRW 43.16 trillion in 2022 to KRW 40.74 trillion in 2025 — so why did operating profit actually rise over that period? Second, how should I read the construction division’s growing reliance on “hi-tech” orders (semiconductor and other advanced-manufacturing facility work)? Third, how much do the non-construction businesses — trading, fashion, resort — actually contribute to results? This is based on the company’s own official IR materials and its 2022-2025 financial data. (Note: for the items where direct DART lookups weren’t working properly this time, I supplemented with Samsung C&T’s official IR materials and verified news coverage.)
Samsung C&T at a Glance — Key Figures
| Ticker Name | Samsung C&T | Ticker | 028260 (KOSPI) |
| Industry | Diversified conglomerate — construction, trading, fashion, resort (co-CEO system) | CEO | Co-CEO structure by division (Construction Division Head Se-cheol Oh, among others) |
| Major Shareholders | Jay Y. Lee and 11 related parties 38.06% (Jay Y. Lee 22.01%, Boo-jin Lee 6.45%, Seo-hyun Lee 7.19%) | Listing | KRX KOSPI |
| H1 2026 Revenue | KRW 22.46T (+13.7% YoY) | Operating Profit | KRW 1.75T (+18.6% YoY) |
| H1 2026 Operating Margin | 7.8% — up from 7.5% a year earlier | 2025 Net Income | KRW 2.44T |
| 2026 New-Order Target (Construction) | KRW 23.5T — KRW 10.45T already booked in H1 (KRW 6.4T of it hi-tech) | 2026 Revenue Target (Company-wide) | KRW 44.5T |
| Debt Ratio (Year-End 2025) | 50.50% — sharply improved from 84.52% in 2022 | Operating Margin (2025) | 8.08% |
| Basis | Samsung C&T’s Q1/Q2 2026 earnings materials plus FY2022-2025 annual financial data (consolidated) | ||
Samsung C&T’s Business Structure — Four Divisions Plus an Equity-Method Bio Stake
Samsung C&T directly operates four business divisions — construction, trading, fashion, and resort — and on top of that holds roughly a 43% equity-method stake in Samsung Biologics, so the biopharma business flows into earnings as equity-method gains rather than as consolidated revenue. In H1 2026, the trading division was the largest by revenue at KRW 8.82 trillion, followed by construction at KRW 7.40 trillion, resort at KRW 2.02 trillion, and fashion at KRW 1.17 trillion. By operating profit, construction led with KRW 313.0 billion, followed by trading at KRW 251.0 billion, fashion at KRW 92.0 billion, and resort at KRW 27.0 billion. Construction accounts for only about a third of revenue but contributes the most to operating profit, making it the division that effectively drives this company’s results.
Within the construction division, the story of the past two to three years has been “hi-tech” exposure. There were periods when semiconductor and other advanced-manufacturing facility work accounted for more than half of the division’s new orders, and in H1 2026, hi-tech still made up KRW 6.4 trillion of KRW 10.45 trillion in new orders — well over half. The company is trying to lower its reliance on a small number of clients by reallocating resources toward its Raemian housing business and nuclear/energy new businesses. Its 2026 company-wide targets — KRW 23.5 trillion in new orders and KRW 44.5 trillion in revenue — represent a sharp upward revision from last year’s targets (KRW 19.6 trillion and KRW 40.7 trillion). Its No.1 construction-capability ranking (ahead of Hyundai E&C and GS E&C) and the 38.06% combined stake held by Chairman Jay Y. Lee and related parties also set it apart from the other large Korean builders.
Samsung C&T’s Financial Trend — Margins Kept Rising Even as Revenue Drifted Down
| Metric | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|
| Revenue | KRW 41.90T | KRW 42.10T | KRW 40.74T | KRW 22.46T |
| Operating Profit | KRW 2.87T | KRW 2.98T | KRW 3.29T | KRW 1.75T |
| Operating Margin | 6.85% | 7.09% | 8.08% | 7.8% |
| Net Income | KRW 2.22T | KRW 2.23T | KRW 2.44T | — (not disclosed by segment) |
| Debt Ratio | 65.74% | 66.38% | 50.50% | — (check the semi-annual filing) |
| YoY Operating Profit | +13.5% | +3.9% | +10.4% | +18.6% |
What stands out most in this table is that operating margin kept climbing — from 6.85% in 2023 to 8.08% in 2025, and 7.8% in H1 2026 — even as revenue stayed flat to slightly down. The construction division alone swung a lot quarter to quarter (Q1 operating profit down 30.2% YoY, Q2 up 71.2% YoY), but trading and fashion improved at the same time, smoothing out the company’s overall earnings volatility. My takeaway is that having four separate divisions gives Samsung C&T a real edge in earnings resilience compared with a single-business builder.
Samsung C&T’s Financial Position — How the Debt Ratio Fell 34pp in Three Years
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Debt Ratio | 84.52% | 65.74% | 66.38% | 50.50% |
| Operating Margin | 5.86% | 6.85% | 7.09% | 8.08% |
| Net Income | KRW 2.04T | KRW 2.22T | KRW 2.23T | KRW 2.44T |
A debt ratio that fell from 84.52% in 2022 to 50.50% in 2025 — a 34-percentage-point drop in three years — is dramatically lower than GS E&C (229.0%) and Daewoo E&C (266.5%) covered earlier, and even lower than the comparatively conservative Samsung E&A (122.4%). This looks like the combined effect of not depending on construction alone — trading, fashion, and resort all generate cash too — plus a steady contribution from Samsung Biologics equity-method gains to net income. That said, I wasn’t able to confirm the detailed H1 2026 balance-sheet figures (total assets, total liabilities) for this analysis. The multi-year improvement in the debt ratio is clear, but readers who want the exact H1 2026 figures should check DART’s semi-annual filing directly.
Samsung C&T’s New Business — Trying to Lower Hi-Tech Reliance in Favor of Nuclear and Energy
The recent strategic shift in the construction division can be summed up as “lower hi-tech reliance.” The 2026 hi-tech order target is set at KRW 6.8 trillion, which, if hit exactly, would bring hi-tech’s share of total orders below 30% (to 28.9%). In its place, the company is putting more weight behind the revival of its Raemian housing business and nuclear/energy new businesses, setting a housing-contract order target of up to KRW 13 trillion and building expectations around participation in nuclear projects. That said, actual H1 results show hi-tech orders at KRW 6.4 trillion — 61.3% of the total — still running well above the stated target, suggesting the actual pace of diversifying away from hi-tech may be slower than planned.
Outside of construction, the trading division has grown into a real presence, posting KRW 251.0 billion in H1 2026 operating profit — close to construction’s KRW 313.0 billion — while the fashion division has also been lifting its margins on steady growth from both in-house and imported brands. On top of that, roughly a 43% equity stake in Samsung Biologics is a consistent contributor to net income via equity-method gains. Samsung Biologics itself posted a record half in H1 2026, with revenue of KRW 2.578 trillion and operating profit of KRW 1.1672 trillion, which flows straight through to Samsung C&T’s equity-method gains. Rather than CAPEX levels, it’s the construction division’s resource allocation across hi-tech, housing, and nuclear, combined with the steady profit contribution from the non-construction businesses, that will shape where this company’s earnings go from here.
Dissecting Samsung C&T’s Results — The Stability That Comes From Divisional Diversity
| Cause | Detail | One-off / Structural |
|---|---|---|
| ① Construction: A Weak Q1, a Strong Q2 | Q1 construction operating profit of KRW 111.0bn (-30.2% YoY), Q2 at KRW 202.0bn (+71.2% YoY) — quarter-to-quarter swings tied to project completion and groundbreaking timing | One-off in nature (project-cycle timing between quarters) |
| ② A Sharp Rise in the Trading Division | Q1 operating profit up 73% YoY, Q2 up 77.5% YoY. Cumulative H1 operating profit of KRW 251.0bn is now close to construction’s KRW 313.0bn | Structural (sustained volume and margin gains in trading) |
| ③ A 34pp Debt-Ratio Improvement, 2022-2025 | From 84.52% to 50.50%. Driven by cash generation spread across four divisions plus the cumulative contribution of Samsung Biologics equity-method gains | Structural (the effect of a diversified business portfolio) |
✅ Three Investment Points
① One of the Lowest Debt Ratios in the Industry (50.50%)
Improved for three straight years, from 84.52% in 2022 to 50.50% in 2025 — lower than GS E&C (229.0%), Daewoo E&C (266.5%), and even Samsung E&A (122.4%), with the diversified business structure translating directly into financial stability.
② Trading and Fashion Growing Together
In H1 2026, trading-division operating profit rose roughly 70%+ year-over-year, closing in on the construction division, while fashion also improved margins on steady growth across in-house and imported brands — offsetting the swings in construction alone.
③ Samsung Biologics Equity Gains Plus the Industry’s No.1 Construction Ranking
Samsung Biologics posted a record H1 2026 (KRW 2.578T revenue, KRW 1.1672T operating profit), feeding into Samsung C&T’s equity-method income, while the construction division leaned on its No.1 construction-capability ranking to set a KRW 23.5 trillion order target.
⚠️ Three Risks
① Hi-Tech Dependence Remains High
Despite a stated strategy of diversifying away from hi-tech, 61.3% of H1 2026 new orders were still hi-tech. Sensitivity to a small set of clients and to the semiconductor capex cycle is easing more slowly than planned.
② A Flat-to-Declining Revenue Trend
Revenue fell from KRW 43.16 trillion in 2022 to KRW 40.74 trillion in 2025. Margin improvement has offset this so far, but it remains to be seen whether margin gains alone can keep compensating without top-line growth.
③ Limited Data Access — Verify Detailed Segment Filings
This analysis wasn’t able to confirm the precise H1 2026 total assets, total liabilities, or detailed net-income figures. Readers should re-check the latest numbers directly in DART’s semi-annual filing before making investment decisions.
My Investment Verdict on Samsung C&T
Compared with the large builders covered so far on this blog, Samsung C&T isn’t fully explained by the “builder” label alone. Construction contributes the most to profit, but the trading, fashion, and resort divisions, together with Samsung Biologics equity-method gains, have propped up results enough that operating margin and the debt ratio both improved even through a period of flat revenue. That said, the construction division’s hi-tech dependence isn’t falling as fast as planned, and revenue itself remains on a gentle downtrend — both worth weighing carefully.
My verdict is to add to a position (buying in tranches). Two things drive that call. First, as the 50.50% debt ratio shows, this is the most conservatively financed of all the large builders and plant contractors covered so far, and its four-division structure limits the damage any single weak segment can do to overall results. Second, the trading division’s rapid profit growth and Samsung Biologics’ record results are showing up at the same time, meaning there are multiple channels for earnings that don’t depend on the construction cycle — that’s an attractive combination.
My view would change on two triggers: ① if hi-tech order dependence fails to come down and a semiconductor-capex slowdown sharply reduces new construction orders; ② if the revenue decline deepens to a point where margin improvement alone can no longer offset it. If either signal is confirmed, I would stop adding to the position and move to the sidelines.
⚠️ Investment Disclaimer
This post is a personal investor’s analysis based on Samsung C&T’s official IR materials and publicly available financial data; it is not investment advice.
All investment decisions should be made at your own judgment and responsibility.
Investing in stocks carries the risk of principal loss.
References
- DART Electronic Disclosure System: https://dart.fss.or.kr
- Samsung C&T Official Website: https://www.samsungcnt.com
- Samsung C&T Newsroom, Q1 2026 Earnings Reference Materials: https://news.samsungcnt.com
- [Q2 2026 Earnings] Samsung C&T Operating Profit Hits KRW 1.032T, Up 37% YoY (Inthenews): https://www.inthenews.co.kr/news/article.html?no=89938
- Samsung C&T’s Construction Division Gains “Nuclear Momentum,” Targets KRW 23.5T in 2026 Orders (Newsis): https://www.newsis.com/view/NISX20260130_0003496081
- Samsung C&T Financial Summary 2022-2025 (Hankyung Markets): https://markets.hankyung.com/stock/028260/financial-summary
- Report on Largest Shareholder Jay Y. Lee’s Stake in Samsung C&T (Digital Today): https://www.digitaltoday.co.kr/news/articleView.html?idxno=668619
- Basis: Samsung C&T’s Q1/Q2 2026 earnings materials plus FY2022-2025 annual financial data (consolidated)
